Participated · Equity · May 2022

Impulse Dynamics builds and commercializes the Optimizer platform, a cardiac contractility modulation (CCM) device designed to improve the quality of life for heart-failure (HF) patients who have limited therapeutic options. Led by CEO Jason Spees, the company focuses on both commercial rollout and continued clinical validation of its technology. More than 12,000 patients have already received CCM therapy across clinical trials and real-world settings, with data demonstrating safety and efficacy for HF patients suffering debilitating symptoms. Current initiatives include the INTEGRA-D multicenter study evaluating the CCM-D HF System and the AIM HIGHer trial. The newly secured capital will be directed toward accelerating commercialization, advancing its future product pipeline, and supporting ongoing clinical trials. The company positions itself as a specialized player tackling unmet needs in the large and growing HF market.

Participated · Series A · Oct 2018

Protembis develops the ProtEmbo Cerebral Protection System, an intra-aortic filter delivered via the left radial artery to deflect embolic material away from cerebral arteries during transcatheter aortic valve replacement (TAVR) and other left-sided heart procedures. The company is advancing ProtEmbo through clinical investigations, including a pivotal FDA‑approved Investigational Device Exemption (IDE) study intended to enroll 250–500 patients in Europe and the US. Protembis is using recent financing to support clinical trials, research and development, and market access for the next‑generation device. Financially, the company completed a €30 million Series B in March 2024 and has secured an additional €20 million venture‑debt facility from the European Investment Bank. The EIB financing is supported by the InvestEU programme and is intended to accelerate product development and regulatory pathways. Protembis is a privately held emerging medtech based in Aachen, Germany. Protembis has developed the ProtEmbo® Cerebral Protection System, an intra-aortic filter device designed to protect the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). The low-profile, non-thrombogenic system shields all cerebral vessels and is delivered via the left radial artery to avoid interference with femoral-delivered TAVR equipment. The ProtEmbo System is currently undergoing clinical investigations, including the PROTEMBO IDE Pivotal Trial (NCT05873816). Protembis says its technology aims to reduce brain injury during left-sided heart procedures, improve patient quality of life, and lower healthcare costs associated with such injuries. The company is privately held and headquartered in Aachen, Germany. Recent financing activity is intended to support the ongoing pivotal trial and pre-commercial programs. Protembis has developed the ProtEmbo, a catheter-based filter advanced via the radial artery to cover arteries leading to the brain while allowing blood cells to pass and blocking embolic particles; the filter is heparin-coated to reduce clotting. The device is designed to minimize particle migration to the brain during transcatheter aortic valve implantation (TAVI/TAVR) and other interventional heart procedures. Protembis reported initial safety and feasibility and demonstrated effectiveness in a first-in-human clinical study. The company plans further clinical studies at leading heart centers in Europe and the U.S. and aims to bring the ProtEmbo to market maturity. Protembis emphasizes a large and growing market opportunity driven by demographic trends and increased use of minimally invasive heart valve interventions. The company has closed institutional backing via a recent Series A to fund development toward commercialization.

Led · Equity · Sep 2018

RenalGuard Solutions markets the RenalGuard platform and develops medical technologies for the cardiac and vascular markets. The company has launched Reprieve Cardiovascular, led by CEO Jim Dillon, to advance Guided Diuretic Therapy for patients with acute decompensated heart failure (ADHF). Reprieve's Guided Diuretic Therapy is intended to enable precise and predictable management of fluid levels in fluid-overloaded heart failure patients and to increase diuretic efficiency. The therapy is described as having potential to speed decongestion while protecting core organ function, shorten hospital stays, reduce readmissions, and improve symptoms such as shortness of breath, ascites, and swelling. Financially, RenalGuard completed a $7M financing announced in September 2018. The round was led by Abiomed with participation from existing investors. RenalGuard Solutions develops the RenalGuard system, designed to protect patients from acute kidney injury (AKI) including contrast-induced AKI by measuring urine output and automatically infusing hydration fluid. The company reports investigator-sponsored studies in Europe that demonstrated RenalGuard’s effectiveness at preventing CI-AKI in at-risk patients. RenalGuard is CE-marked and is sold in Europe and certain countries worldwide via a network of distributors. RenalGuard Solutions is led by Chairman Ethan Benovitz and is conducting the CIN-RG pivotal study in the United States to support a planned Premarket Approval filing with the U.S. Food and Drug Administration. The company plans to use new funding to complete its ongoing pivotal trial by year-end to support U.S. marketing approval in 2018, extend marketing and sales activities in Europe and other regions, and expand R&D into additional clinical indications. The device and ongoing trial position the company for regulatory progress and broader commercial expansion where the technology is available.

Participated · Series B · Oct 2017

Magenta Medical is focused on developing miniaturized blood pumps intended to provide minimally invasive support to the native heart during acute episodes of dysfunction. Its lead product, the Elevate™ percutaneous left ventricular assist device (pLVAD), is in clinical trials for at least two indications: high-risk percutaneous coronary interventions (HR-PCI) and cardiogenic shock. The company plans to use the new funding to advance its U.S. clinical programs across multiple mechanical circulatory support (MCS) indications and to pursue FDA approval for the Elevate System in HR-PCI patients. Magenta is led by CEO Dr. David Israeli and is based in Kadima, Israel. The company positions its technology to support patients at risk of dangerously low blood pressure and compromised organ perfusion during acute cardiac events. Magenta Medical is a Kadima, Israel–based company developing miniaturized blood pumps to provide minimally-invasive support to the native heart. Its lead product, the Elevate percutaneous left ventricular assist device, is currently in clinical testing. The company intends to secure FDA approval for at least two indications: patients undergoing high-risk coronary interventions and patients with cardiogenic shock. Magenta plans to use new funding to advance the clinical programs of Elevate in the United States toward its first FDA approval. The company was founded by serial entrepreneurs Professor Ehud Schwammenthal and Yosi Tuval, who previously founded Ventor Technologies. Magenta is led by CEO Dr. David Israeli. Magenta Medical develops a catheter-based flow pump inserted on the venous side to help kidneys eliminate salt and relieve fluid buildup in heart-failure patients. The device delivers therapy for up to 24 hours and does not leave a permanent implant. Company executives say the therapy aims to reduce hospital readmissions and ICU stays tied to deteriorating kidney function. Magenta’s technology is already in clinical trials in Europe, and the current funds will be used to obtain a CE Mark. The firm plans to share European trial data with the FDA to determine a U.S. regulatory pathway and hopes to reach agreement with the agency on that clinical pathway. Magenta was founded in October 2012 by a cardiologist and a mechanical engineer; David Israeli is the company’s CEO. Magenta Medical develops novel therapeutic approaches to the treatment of congestive heart failure. The company is described in the article as pioneering a new therapeutic approach for CHF, a condition characterised as an epidemic in the Western world. Magenta was founded in October 2012 by CEO Prof. Ehud Schwammenthal and mechanical engineer Yosi Tuval and is based in Tel Aviv, Israel. The company raised $4M in seed funding from Pitango Venture Capital. As part of the investment, Pitango partner Dr. David Israeli will join Magenta's board of directors. No additional financial terms or use-of-proceeds details were disclosed in the article.

Participated · Series C · Apr 2017

ALung Technologies develops the Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung that removes carbon dioxide independently of the lungs using a process called Respiratory Dialysis®. The company focuses on low‑flow extracorporeal carbon dioxide removal (ECCO2R) to treat patients with acute respiratory failure. The Hemolung RAS has been used to treat hundreds of patients outside the United States since 2013 and received FDA Expedited Access Pathway designation in 2015. ALung plans to use new funding to support a U.S.‑based pivotal clinical trial aimed at FDA approval and broader availability in the United States. The company is privately held and headquartered in Pittsburgh; it was founded in 1997. The recent financing strengthens clinical and commercialization plans while adding strategic partners to its board and advisory ranks. ALung Technologies is a privately held Pittsburgh-based developer and manufacturer of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies, notably the Hemolung RAS which uses a Respiratory Dialysis® process. The Hemolung RAS is positioned as a dialysis-like alternative or supplement to mechanical ventilation for acute respiratory failure, with applications in ARDS and COPD. The company reports CE mark clearance in 2013, global clinical adoption at leading centers, and that hundreds of patients have been treated with the technology. ALung is pursuing a share of the estimated $6 billion acute respiratory failure market. The company plans to use recent financing to support continued commercialization and to complete work required to obtain IDE approval for a U.S.-based clinical trial following its Expedited Access Pathway (EAP) designation. ALung was founded in 1997 and is backed by individual investors and venture firms named in its filings. ALung Technologies develops and manufactures the Hemolung Respiratory Assist System (RAS), a low‑flow, minimally invasive extracorporeal carbon dioxide removal (ECCO2R) device. The Hemolung provides Respiratory Dialysis® as an alternative or supplement to mechanical ventilation with indications including acute exacerbation of COPD and ARDS. The device was tested at 43 hospitals in 13 countries and following a successful clinical trial in Germany received regulatory clearances in Europe and Canada. ALung initiated a controlled launch in mid‑2013 and has accelerated commercial roll‑out in Germany, the UK, France, Canada, and Australia. The Hemolung RAS is currently approved in 29 countries across Europe, the Middle East, and Asia‑Pacific. The company says it will use new financing to accelerate global commercialization of the technology. ALung Technologies develops extracorporeal respiratory assist devices, principally the Hemolung Respiratory Assist System (RAS), a dialysis-like extracorporeal carbon dioxide removal (ECCO2R) system. The Hemolung RAS provides Respiratory Dialysis® as a simple, minimally invasive alternative or supplement to mechanical ventilation and has indications for ARDS and acute exacerbation of COPD. The device is approved for sale in Europe and Canada, and ALung has established direct commercial operations in Germany, France, and the United Kingdom while entering additional markets through distribution partners. The company intends to use new capital to support global commercialization and to further develop next-generation products and platform technologies for less-invasive extracorporeal lung support. To date ALung has raised $56 million in equity capital, and the recent financing will primarily support the global launch of the Hemolung RAS. ALung's lead product, HemoLung, is an extracorporeal artificial lung that removes carbon dioxide from blood while infusing oxygen via a catheter into the femoral or jugular vein. The device is intended for patients with acute respiratory failure to help them avoid mechanical ventilation. Four months after receiving CE Mark approval, ALung is commercializing HemoLung in Germany, France, the UK and Canada and plans sales in Canada and Australia. The company has set up 10 reference centers, is hiring clinical specialists and support staff, and is seeking distributors in Europe, Canada and Australia. ALung estimates a patient population of about 900,000 and a market opportunity of roughly $4.6 billion. The company was started in 1997 by Dr. Brack Hattler and Bill Federspiel.